

## **PARTICULARS TO APPEAR ON THE OUTER BOX**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

SELGIAN 4 mg Film-Coated Tablets

### **2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

(-) Selegiline hydrochloride, 4 mg per tablet

### **3. PHARMACEUTICAL FORM**

Tablets

### **4. PACKAGE SIZE**

3 x 10 tablets (pictogram of a tablet)  
or 5 x 10 tablets (pictogram of a tablet)  
or 10 x 10 tablets (pictogram of a tablet)  
or 50 x 10 tablets (pictogram of a tablet)

### **5. TARGET SPECIES**

Dogs

### **6. INDICATION(S)**

For the treatment of behavioural disorders of emotional origin including anxiety, depression, unsociable behaviour, hyperactivity and phobias.

### **7. METHOD AND ROUTE(S) OF ADMINISTRATION**

One tablet orally per 8 kg bodyweight, once daily (weigh the dog to ensure accuracy of dosing).

### **8. SPECIAL WARNING(S), IF NECESSARY**

Do not administer to pregnant or suckling bitches. For full details of dosage administrations, precautions and disposal advice see package leaflet.

### **9. EXPIRY DATE**

Exp:

### **10. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C. Keep the blister strips in the outer carton.

**11. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

See package leaflet.

**12. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE**

POM-V
-------

To be supplied only on veterinary prescription. For animal treatment only.

**13. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of reach and sight of children.

**14. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Ceva Santé Animale, 10, av. de La Ballastière, Libourne, 33500, France

**15. MARKETING AUTHORISATION NUMBER(S)**

Vm 14966/4000

**16. MANUFACTURER’S BATCH NUMBER**

Lot:

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

SELGIAN 4 mg

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Selegiline hydrochloride, 4 mg

(Selegiline (as hydrochloride) 3.35 mg)

**3. PHARMACEUTICAL FORM**

Tablets for dogs

**4. BATCH NUMBER**

**5. EXPIRY DATE**

**6. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only

## **PACKAGE LEAFLET**

### **1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

**Marketing Authorisation Holder:**

Ceva Santé Animale, 10, av. de La Ballastière, Libourne, 33500, France

**Marketed by:**

Explorer House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, United Kingdom

**Manufacturer responsible for batch release:**

Ceva Santé Animale, ZI Très le Bois, 22 600 Loudeac, France

### **2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Selgian 4 mg tablets

### **3. STATEMENT OF THE ACTIVE SUBSTANCE (S) AND OTHER INGREDIENTS**

(-) Selegiline hydrochloride: 4. mg per tablet.

### **4. INDICATION(S)**

- i)* Treatment of behavioural disorders of purely emotional origin: depression, anxiety.
- ii)* In association with behaviour therapy, treatment of signs of emotional origin observed in behavioural conditions such as overactivity, separation problems, generalised phobia and unsocial behaviour.

Emotional disorders are characterised by a modification of feeding, drinking, auto-stimulatory behaviour, sleep, exploratory behaviour, aggression related to fear and/or irritation, social behaviour and somatic disorders (tachycardia, emotional micturition...).

### **5. CONTRAINDICATIONS**

1. Owing to its IMAO properties, (–) selegiline hydrochloride may act on prolactin secretion. In the absence of specific studies, it is recommended that the product should not be administered to pregnant and lactating bitches.
2. Do not administer Selgian from the day before until the day after anaesthesia or tranquillisation performed with an alpha-2 agonist.
3. Do not administer Selgian concomitantly with pethidine, fluoxetine or phenothiazines.

The narcotic action of morphine is potentiated by the product.

## 6. ADVERSE REACTIONS

Trials have shown that some dominant dogs, with behavioural disorders but no signs of aggression, may become aggressive after treatment. Those previously showing aggression may have this enhanced. Appropriate training is essential in such cases. At the dosage recommended, secondary effects have not been observed in the majority of animals.

## 7. TARGET SPECIES

Dogs

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For oral administration to dogs. The dose rate is 0.5 mg of (-) selegiline hydrochloride per kg body weight once daily. This is equivalent to:

Dog weight in kg	Number of tablets Selgian 4mg
≥1.5 < 3	$\frac{1}{4}$
≥3 < 5	$\frac{1}{2}$
≥5 < 7	$\frac{3}{4}$
≥7 < 9	1
≥9 < 11	1 $\frac{1}{4}$
≥11 < 13	1 $\frac{1}{2}$
≥13 < 15	1 $\frac{3}{4}$
≥15 < 17	2

For dogs weighing more than 17 kg, the use of Selgian® 10 mg is advisable in order to reduce the number of tablets to be administered.

The treatment should be continued until the clinical condition is stable, when treatment must cease.

The minimum treatment period recommended is 2 months, based on the clinical trials results:

- The treatment period was 2 to 3 months for 20 % of the dogs
- The treatment period was 4 to 5 months for 50 % of the dogs
- The treatment period was 6 to 7 months for 20 % of the dogs
- The treatment period was > 7 months for 10 % of the dogs

If no clinical improvement is observed after two months, further dosing is not indicated.

The treatment must be stopped suddenly without gradual dose reductions.

## 9. ADVICE ON CORRECT ADMINISTRATION

Weight the dog before starting a course of therapy to ensure accuracy of dosing.

## 10. SPECIAL STORAGE PRECAUTIONS

Do not store above 25°C.

## 11. SPECIAL WARNING(S)

Keep out of reach of children.

## 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## 13. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

March 2023

## 14. OTHER INFORMATION

### • Pharmacodynamics:

(-) Selegiline hydrochloride has the following properties:

\* Inhibitor of monoamine oxidase (IMAO-B) at the therapeutic dose in the dog; thus it modifies the concentrations of monoaminergic neurotransmitters.

### • Pharmacokinetics:

(-) Selegiline hydrochloride is quickly absorbed after oral administration. The oral bioavailability ranges from 65 to 95% in the dog. Selegiline binds rapidly and durably onto the specific cerebral receptors. The duration of the pharmacological effect following such binding is independent of the maintenance of blood levels. Selegiline is quickly metabolised into desmethylselegiline, 1-amphetamine and 1-metamphetamine. At the therapeutic dose recommended in the dog, these derivatives have no pharmacological activity.

**Presentations:** Selgian 4 mg: Pack of 3 blisters of 10 tablets or Pack of 10 blisters of 10 tablets

**Vm** 14966/4000


POM-V

For animal treatment only

## MARKETING AUTHORISATION NUMBER

Vm 14966/4000

Selgian® is a trademark.



Approved: 21 June 2023